ArticleFrontiers in immunology2026
circPVT1 regulates EMT and induces macrophage polarization to promotes the progression of renal cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Renal cell carcinomas (RCC) are resistant to chemotherapy and radiotherapy, and effective treatment options remain limited. Immunotherapy has emerged as a promising approach, and circular RNAs (circRNAs) are increasingly recognized as key regulators of tumor immunity. This study aims to elucidate the regulatory relationship between circPVT1 and antitumor immunosuppression in RCC. Methods: CircPVT1 expression and its prognostic value were analyzed in RCC samples. The effects of circPVT1 knockdown on RCC cell proliferation, invasion, and metastasis were examined Results: CircPVT1 was highly expressed in RCC and correlated with poor prognosis. Knockdown of circPVT1 significantly suppressed cell proliferation, invasion, and metastasis. Singlecell sequencing revealed increased macrophage infiltration in the circPVT1high group. ELISA results demonstrated that circPVT1 knockdown reduced tumor cell secretion of IL4, IL10, and TGFβ, thereby promoting macrophage polarization toward the M1 phenotype. Mechanistically, circPVT1 promoted RCC progression by regulating EMT. Furthermore, a nanotherapeutic system containing circPVT1 inhibitors effectively inhibited RCC growth. Discussion: These findings indicate that circPVT1 plays a critical role in RCC immune evasion by modulating macrophage polarization and EMT. Therefore, circPVT1 may be a predictor of ccRCC immune evasion and a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.